Lung Cancer Failure Isn't The End For Merck KGaA And GSK's Bintrafusp

But Frontline NSCLC Was Biggest Opportunity

 
• By Andrew McConaghie
Merck KGaA Darmstadt
Merck KGaA, Darmstadt: the company is counting on its oncology pipeline to boost revenues to €2bn by 2022. • Source: Getty Images

More from Business

More from Scrip